Replimune Group (REPL) Stock Rating Lowered by Zacks Investment Research

Replimune Group (NASDAQ:REPL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday.

According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

A number of other research firms have also recently issued reports on REPL. Leerink Swann initiated coverage on Replimune Group in a report on Tuesday, August 14th. They set an “outperform” rating and a $25.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Replimune Group in a report on Tuesday, August 14th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, BMO Capital Markets initiated coverage on Replimune Group in a report on Tuesday, August 14th. They set an “outperform” rating and a $31.00 price target on the stock.

Replimune Group stock opened at $14.99 on Thursday. Replimune Group has a 52-week low of $10.52 and a 52-week high of $23.55.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). On average, analysts predict that Replimune Group will post -1.21 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. bought a new position in shares of Replimune Group during the 3rd quarter worth $5,379,000. TIAA CREF Investment Management LLC bought a new position in shares of Replimune Group during the 3rd quarter worth $164,000. Redmile Group LLC bought a new position in shares of Replimune Group during the 3rd quarter worth $35,307,000. Zimmer Partners LP bought a new position in shares of Replimune Group during the 3rd quarter worth $322,000. Finally, Bain Capital Life Sciences Investors LLC bought a new position in shares of Replimune Group during the 3rd quarter worth $45,707,000. Hedge funds and other institutional investors own 32.99% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Story: How To Calculate Debt-to-Equity Ratio

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit